Drug trial aims to stop cancer before it starts
NCT ID NCT03236428
Summary
This study is testing whether the drug daratumumab can prevent or delay the progression to active multiple myeloma in people with high-risk early-stage conditions. It involves 42 adults with either high-risk MGUS or low-risk smoldering multiple myeloma. The goal is to see if this treatment can keep the condition from becoming an active cancer that requires more intensive therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Karmanos Cancer Insitute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States
Conditions
Explore the condition pages connected to this study.